Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2014 12/12/2014 12/15/2014 12/16/2014 12/17/2014 Date
100.22(c) 100.45(c) 93.95(c) 92.08(c) 96.45(c) Last
513 488 477 410 838 112 741 482 573 234 Volume
-0.52% +0.23% -6.47% -1.99% +4.75% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 40,1 M
EBIT 2014 -368 M
Net income 2014 -362 M
Finance 2014 486 M
Yield 2014 -
Sales 2015 48,2 M
EBIT 2015 -210 M
Net income 2015 -208 M
Finance 2015 568 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 173x
EV / Sales 2015 142x
Capitalization 7 420 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
52m ago ALNYLAM PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
1h ago ALNYLAM PHARMACEUTICALS : Elects Michael W. Bonney to Its Board of Directors
4h ago ALNYLAM PHARMACEUTICALS : Reports Positive Initial Results for ALN-AT3, an Inves..
1d ago ALNYLAM PHARMACEUTICALS : Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusi..
2d ago Alnylam Reports Commencement of ENDEAVOUR Phase 3 Clinical Trial with Revusir..
2d ago ALNYLAM PHARMACEUTICALS : and The Medicines Company Commence Phase 1 Clinical Tr..
2d ago ALNYLAM PHARMACEUTICALS : Begins Endeavour Phase 3 Clinical Trial with Revusiran..
6d ago ALNYLAM PHARMACEUTICALS : Introduces Pipeline Growth Strategy for RNAi Therapeut..
More news
Sector news
1d ago MEDIVATION : Announces Participation at Upcoming Investor Conference
1d ago QUINTILES TRANSNATIONAL : CEO Tom Pike to Present at J.P. Morgan Healthcare Conf..
1d agoDJUnited Therapeutics Cuts Top Executive's Pay, Names Co-Chief
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF